结直肠癌 (CRC) 是全球第二大癌症相关死亡原因，p53 作为一种广泛认可的肿瘤抑制因子，有助于结直肠癌的发展。泛素特异性蛋白酶 36 (USP36) 属于去泛素化酶家族，参与多种癌症的肿瘤进展。然而，USP36 在 CRC 中调节 p53 信号通路的潜在分子机制尚不清楚。在这里，我们的研究表明 USP36 在 CRC 组织中增加，并与不良预后相关。从功能上讲，USP36升高可以促进体外和体内CRC细胞的增殖、迁移和侵袭。从机制上讲，USP36 可以通过 K162 残基的去泛素化与 RBM28 相互作用并稳定 RBM28。此外，上调的RBM28可以与p53结合，抑制其转录活性，从而使p53信号通路失活。总的来说，我们的研究确定了新的 USP36/RBM28/p53 轴及其在促进 CRC 细胞增殖和转移中的作用，这为 CRC 治疗提供了一种有前景的治疗策略。© 2024。作者。

Colorectal cancer (CRC) stands as the second most common cause of cancer-related mortality globally and p53, a widely recognized tumor suppressor, contributes to the development of CRC. Ubiquitin-specific protease 36 (USP36), belonging to the deubiquitinating enzyme family, is involved in tumor progression across multiple cancers. However, the underlying molecular mechanism in which USP36 regulates p53 signaling pathway in CRC is unclear. Here, our study revealed that USP36 was increased in CRC tissues and associated with unfavorable prognosis. Functionally, elevated USP36 could promote proliferation, migration, and invasion of CRC cells in vitro and in vivo. Mechanistically, USP36 could interact with and stabilize RBM28 via deubiquitination at K162 residue. Further, upregulated RBM28 could bind with p53 to suppress its transcriptional activity and therefore inactivate p53 signaling pathway. Collectively, our investigation identified the novel USP36/RBM28/p53 axis and its involvement in promoting cell proliferation and metastasis in CRC, which presents a promising therapeutic strategy for CRC treatment.© 2024. The Author(s).